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We evaluated intracranial failure after hippocampus‑avoidance‑prophylactic cranial irradiation 
(HA‑PCI) for limited‑stage small‑cell lung cancer (SCLC). Data of 106 patients who received PCI with 
25 Gy were retrospectively reviewed. The patients were divided into two groups based on whether 
they underwent HA‑PCI: the HA‑PCI group (n = 48) and the conventional PCI (C‑PCI) group (n = 58). 
Twenty‑one patients experienced intracranial failure: 11 and 10 patients in the C‑PCI and HA‑PCI 
groups, respectively. Using the log‑rank test, the intracranial failure rate was not significantly different 
between the groups (p = 0.215). No clinical factor was significantly associated with intracranial failure 
in multivariate Cox regression analysis, but HA‑PCI tended to be associated with increased incidence 
of intracranial failure (HR 2.87, 95% CI 0.86–9.58, p = 0.087). Among patients who received HA‑PCI, 
two developed peri‑hippocampal recurrence. A higher thoracic radiotherapy dose (≥ 60 Gy) was 
significantly associated with DFS (HR 0.52, p = 0.048) and OS (HR 0.35, p = 0.003). However, HA‑PCI 
was associated with neither DFS nor OS. Although HA‑PCI may be associated with an increased risk of 
intracranial failure, HA‑PCI did not impair disease control or survival. Future prospective randomized 
trials are needed to reach a definite conclusion.
Abbreviations
EQD2  Equivalent dose in 2 Gy fractions, α/β = 10
CI  Confidence interval
CR  Complete response
CRT  Chemoradiation
CT  Computed tomography
C-PCI  Conventional prophylactic cranial irradiation
DFS  Disease-free survival
HA  Hippocampal avoidance
HR  Hazard ratio
MRI  Magnetic resonance imaging
OS  Overall survival
PCI  Prophylactic cranial irradiation
PR  Partial response
RT  Radiotherapy
SCLC  Small-cell lung cancer
SRS  Stereotactic radiosurgery
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VMAT  Volumetric-modulated arc therapy
WBRT  Whole-brain radiotherapy
Small-cell lung cancer (SCLC) is one of the most aggressive types of thoracic malignancy, and its associated 
outcome is poor. However, survival has recently improved because of advancements in early diagnosis and thera-
peutic  modalities1,2. The survival of SCLC patients may be affected by brain metastasis and prophylactic cranial 
irradiation (PCI), which is the standard treatment for SCLC patients who have a favorable response to their 
initial  treatment3. Furthermore, PCI for patients with extensive disease and a good response to chemotherapy 
increases the overall survival (OS). Therefore, PCI is essential for improving survival and preserving patients’ 
quality of  life4. However, a recent Japanese phase III multicenter randomized trial demonstrated that compared 
with observation, PCI did not result in longer OS in SCLC patients with extensive  disease5.
There are many concerns and issues regarding administering irradiation to the naive brain, thereby mak-
ing some physicians and patients reluctant about PCI. Although the irradiation dose in PCI has been reduced, 
previous studies continued to report that PCI led to significant impairments in short-term memory and cogni-
tive  functions6–8. Such neurocognitive deficit problems following PCI have led to the consideration of the risks/
benefits of PCI and whether PCI meets the fundamental therapeutic goal of preserving the quality of life of 
cancer patients.
Therefore, strategies to reduce radiation doses to the brain or perform active surveillance have been  proposed9. 
Additionally, intensity-modulated radiotherapy (IMRT) and pre-treatment brain MRI allowed the delivery of 
hippocampal-avoidance (HA)-PCI as an alternative option. Since Ghia et al. reported that only 3.3% of lesions 
were within 5 mm of the hippocampus compared with 86.4% of lesions within > 15 mm from the  hippocampus10, 
HA-whole-brain RT (WBRT) has been widely used for treating brain metastasis. Moreover, a phase II study 
(RTOG 0933) revealed that HA during WBRT is associated with memory preservation, and a recent prospec-
tive study of HA-PCI suggested a benefit of hippocampal sparing in limiting neuropsychological  deficits11,12. 
Although the safety and feasibility of HA-PCI have been demonstrated, a risk of recurrence in the spared area 
has also been  reported10,11,13.
To date, the specific location of intracranial failure after HA-PCI remains unknown, and improved prediction 
of the sites of intracranial failure after HA-PCI may allow for HA-PCI to be the standard of care for SCLC. Thus, 
this study aimed to evaluate the patterns of intracranial failure after HA-PCI in SCLC patients, with a particular 
focus on the specific site of recurrence with regard to the peri-hippocampal area. We also compared intracranial 
failure rates between the HA-PCI and conventional PCI (C-PCI) groups.
Results
Patients and treatment characteristics. Overall, 106 patients received a radiation dose of 25 Gy in 10 
fractions and were included in this analysis. All patients had negative brain MRI results 3 months before the 
start of PCI or at SCLC diagnosis. Forty-eight patients received HA-PCI using helical tomotherapy (Accuray, 
Sunnyvale, CA, USA). The remaining 58 patients received conventional PCI (C-PCI) via parallel-opposed lateral 
portals using a 6-MV photon linear accelerator. Patient and treatment characteristics are described in Table 1.
The median age of the patients was 65 (range 37–82) years, and most patients (87.7%) were male. Further-
more, most patients (83%) had locally advanced disease with stage IIIA/B according to the 7th edition American 
Joint Committee on Cancer staging system. In total, 98 patients (92.5%) received concurrent chemoradiation 
(CRT) as their initial treatment, four received sequential CRT, and three underwent primary surgery. The most 
commonly used chemotherapy regimen was etoposide/cisplatin in 102 patients (96.2%). Sixty-nine patients 
received four chemotherapy cycles and 36 received six cycles.
The median radiation dose to primary and/or lymphatic thoracic lesions was 60 Gy (EQD2, Equivalent dose 
in 2 Gy fractions [EQD2], α/β = 10) in 30 fractions. About half of the patients received IMRT to the lung. The 
median interval between initial diagnosis and PCI was 112 days, and the median interval between the last treat-
ment and PCI was 28 days.
The 106 patients were divided into two groups based on whether they received HA-PCI: 48 in the HA-PCI 
group and 58 in the C-PCI group. There were no significant differences in age, sex, performance status, stage, 
or treatment modality between the two groups. However, more patients in the HA-PCI group compared to the 
C-PCI group received six chemotherapy cycles (43.8% vs. 25.9%, p = 0.043) and a higher dose of thoracic RT 
(≥ 60 Gy, 15.6% vs. 88.9%, < 0.001). Patients in the HA-PCI group were treated recently, and IMRT was more 
commonly used for their treatment; all HA-PCI plans included IMRT, and thoracic RT was also delivered more 
frequently using IMRT in this group than in the C-PCI group (93.8% vs. 10.9%, p < 0.001). Nevertheless, patients 
in the C-PCI group showed a higher complete response (CR) rate (13.8% vs. 2.1%, p = 0.023) compared to their 
initial treatment.
Intracranial failure and related factors. The median follow-up duration in all patients was 21 months; 
it was 18 months in the HA-PCI group and 29 months in the C-PCI group. Twenty-one patients experienced 
intracranial failure: 11 (19%) in the C-PCI group and 10 (20.8%) in the HA-PCI group. The cumulative incidence 
of intracranial failure was not significantly different between the two groups (p = 0.215; Fig. 1).
Factors associated with intracranial failure are shown in Table 2. In the univariate analysis, older age and 
male sex showed a trend toward an increased HR. No clinical factor was significantly associated with intracranial 
failure in multivariate analysis, but HA-PCI tended to be associated with increased incidence of intracranial 
failure (HR 2.87, 95% CI 0.86–9.58, p = 0.087).
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Total C-PCI HA-PCI
p valuen = 106 % n = 58 % n = 48 %
Age, years
Median 65 65 64 0.424
(Range) (37–82) (53–82) (37–79)
Sex
Male 93 87.7 54 93.1 39 81.3 0.064
Female 13 12.3 4 6.9 9 18.8
ECOG PS
0, 1 101 95.3 55 94.8 45 93.8 0.842
2 5 4.7 3 5.2 2 4.2
T stage
T1 17 16.0 7 12.1 10 20.8 0.127
T2 33 31.1 21 36.2 12 25.0
T3 25 23.6 10 17.2 15 31.3
T4 31 29.2 20 34.5 11 22.9
N stage
N0 12 11.3 8 13.8 4 8.3 0.741
N1 13 12.3 8 13.8 5 10.4
N2 57 53.8 30 51.7 27 56.3
N3 24 22.6 12 20.7 12 25.0
AJCC stage (7th edition)
I 7 6.6 5 8.6 2 4.2 0.796
II 11 10.4 6 10.3 5 10.4
IIIA 43 40.6 22 37.9 21 43.8
IIIB 45 42.5 25 43.1 20 41.7
Initial treatment
RT alone 1 0.9 0 0.0 1 2.1 0.063
Concurrent CRT 98 92.5 51 87.9 47 97.9
Sequential CRT 4 3.8 4 6.9 0 0.0
Surgery 3 2.8 3 5.2 0 0.0
Chemotherapy regimen
None 1 0.9 0 0.0 1 2.1 0.114
EP 102 96.2 55 94.8 47 97.9
Others 3 2.8 3 5.2 0 0.0
Chemotherapy cycles
4 69 65.1 43 74.1 26 54.2 0.043
6 36 34.0 15 25.9 21 43.8
Thoracic RT dose (Gy)
Median 54 54 63 < 0.001
(Range) (30.6–70.2) (37.-64.5) (30.6–72)
Thoracic RT fraction size (Gy)
Median 2 2 2.1 0.097
(Range) (1.5–15) (1.8–15) (1.5–2.5)
Thoracic RT fractions
Median 30 28 30 0.036
(Range) (3–35) (3–33) (17–35)
Thoracic RT total dose (EQD2)
< 60 Gy 38 84.4 5 11.1 43 47.8 < 0.001
≥ 60 Gy 7 15.6 40 88.9 47 52.2
Thoracic RT modality
3D CRT 52 50.5 49 89.1 3 6.3 < 0.001
IMRT 51 49.5 6 10.9 45 93.8
Initial treatment response
CR 9 8.5 8 13.8 1 2.1 0.023
PR 94 88.7 47 81.0 47 97.9
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Table 1.  Patient and treatment characteristics. C-PCI conventional prophylactic cranial irradiation, HA-PCI 
hippocampus-avoidance PCI, ECOG PS Eastern Cooperative Oncology Group Performance Status, AJCC 
American Joint Committee on Cancer, RT radiotherapy, CRT chemoradiotherapy, EP etoposide/cisplatin, 
EQD2 Equivalent dose in 2 Gy fractions, α/β = 10, 3D-CRT 3-dimensional conformal radiotherapy, IMRT 
intensity-modulated radiotherapy, CR complete response, PR partial response, SD stable disease.
Total C-PCI HA-PCI
p valuen = 106 % n = 58 % n = 48 %
PCI modality
3D CRT 57 53.8 56 96.6 0 0.0 < 0.001
IMRT 49 46.2 2 3.4 48 100.0
Interval, initial treatment to PCI (days)
Median 112 125 105 0.003
(Range) (68–312) (69–312) (68–167)
Interval, last treatment to PCI (days)
Median 28 28 27 0.424
(Range) (0–146) (7–146) (0–116)
Treatment period
Median 2014 2011 2017 < 0.001
(Range) (2007–2018) (2007–2016) (2015–2018)
Figure 1.  Kaplan–Meir curves of the cumulative incidence of intracranial failure in the conventional 
prophylactic cranial irradiation (C-PCI) and hippocampal-avoidance (HA)-PCI groups.
Table 2.  Prognostic factors for intracranial failure. RT radiotherapy, 3D-CRT 3-dimensional conformal 
radiotherapy, IMRT intensity-modulated radiotherapy, CR complete response, PR partial response, SD stable 
disease, PCI prophylactic cranial irradiation, HR hazard ratio, mo months.
Variables
Univariate analysis Multivariate analysis
HR
95% CI for HR
p HR
95% CI for HR
pLower Upper Lower Upper
Age (years) ≥ 65 (vs. < 65) 0.46 0.19 1.14 0.095 0.6 0.19 1.92 0.391
Sex F (vs. M) 2.4 0.88 6.58 0.088 1.68 0.47 6.01 0.424
T stage T3, 4 (vs. T1, 2) 1.12 0.49 2.75 0.737 1.9 0.61 5.92 0.271
N stage N3 (vs. N0-2) 1.66 0.64 4.33 0.298 1.99 0.54 7.28 0.301
Chemotherapy cycles 6 (vs. 4) 0.78 0.3 2.03 0.61 0.86 0.26 2.8 0.803
Initial treatment response PR/SD (vs. CR) 0.77 0.23 2.65 0.681 1.4 0.16 12.2 0.761
Interval, diagnosis to PCI (mo) > 3 (vs. ≤ 3 ) 0.91 0.38 2.16 0.827 1.71 0.59 4.97 0.325
Locoregional failure Yes (vs. No) 1.03 0.44 2.44 0.939 0.81 0.29 2.31 0.697
Hippocampal-avoidance PCI Yes (vs. No) 1.76 0.71 4.39 0.224 2.87 0.86 9.58 0.087
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Patterns of intracranial failure and salvage treatment. Most patients (8 patients, 80%) who devel-
oped brain metastasis after HA-PCI had limited disease with one or two lesions; the remaining patients had 
multiple brain metastases (more than seven lesions) or leptomeningeal seedings. All patients with intracra-
nial failure received additional brain RT; seven underwent stereotactic radiosurgery (SRS) with 13–16 Gy, two 
received 30 Gy in 10 fractions of IMRT to all recurrent tumors, and one received 30 Gy of WBRT because of 
leptomeningeal seedings.
In the C-PCI group, most of patients (9 out of 11 patients, 81.8%) had 1 or 2 brain metastases; of the 11 
patients, 6 had SRS, 2 had surgery, 1 had WBRT, and 2 with other distant recurrence had only systemic treatment.
Among patients who received HA-PCI and experienced intracranial failure, two developed brain metastasis in 
the peri-hippocampal area (Fig. 2), and they developed intracranial failure 17 and 3 months after HA-PCI. Both 
patients had N3 disease at initial diagnosis, received six chemotherapy cycles, and showed partial response (PR) 
after the initial treatment. The mean irradiated doses to the peri-hippocampal recurrent tumor were 24.8 and 
23.6 Gy, respectively, and the minimum doses were 14.8 and 21.6 Gy, respectively (Fig. 2). In the C-PCI group, 
only 1 patient showed peri-hippocampal recurrence at multiple other intracranial sites (> 9).
Disease‑free survival and overall survival. For all patients, the median disease-free survival [DFS] and 
OS were 8 and 24 months, respectively. Kaplan-Meir survival curves for the DFS and OS of each group are shown 
in Fig. 3. Both DFS and OS were not significantly different between groups (C-PCI vs. HA-PCI group: median 
DFS, 8 vs. 8 months, p = 0.369 and median OS, 23 vs. 24 months, p = 0.609).
Prognostic factors for DFS and OS are shown in Table 3. In the univariate analysis, only a higher thoracic 
RT dose (equivalent dose in 2 Gy fractions [EQD2] ≥ 60 Gy) was associated with a decreased risk of recurrence 
(hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.31–0.99, p = 0.049); however, no factor was significant 
for DFS in multivariate analysis. N stage and thoracic RT dose were associated with OS in the univariate analysis. 
The multivariate analysis revealed that treatment response showed a trend toward statistical significance for OS 
(HR 4.04, 95% CI 0.97–17.16, p = 0.058). HA-PCI was not associated with either DFS or OS.
Discussion
We evaluated the rate and pattern of intracranial failure after HA-PCI in limited-stage SCLC patients. Although 
two patients experienced peri-hippocampal recurrence after HA-PCI, HA-PCI did not significantly increase the 
intracranial failure rate. DFS and OS did not significantly differ between HA-PCI and C-PCI.
Although the log-rank test results were not significant (p = 0.215), as shown in Fig. 2, the intracranial failure 
rate might increase in the HA-PCI group with longer follow-up. However, in two patients with recurrence in 
the peri-hippocampal area in the HA-PCI group, the lesions occurred at margins, and one of them received a 
sufficient radiation dose (mean dose, 23.6 Gy; minimum dose, 21.6 Gy)14. Therefore, the recurrence could not 
have been because of HA. Based on our findings, whether HA-PCI increases intracranial failure should be care-
fully assessed.
Figure 2.  Radiation dose distribution and sites of intracranial failure (ICF) in two patients with peri-
hippocampal recurrences after hippocampal-avoidance prophylactic cranial irradiation. Patient (A) was a 
73-year-old man, and ICF developed 17 months after HA-PCI. Patient (B) was a 60-year-old man, and ICF 
developed 3 months after HA-PCI.
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Effeney et al. reported that among patients who did not receive PCI, 18.3% developed hippocampal metastasis, 
resulting in a higher incidence than that in non-SCLC  patients15; however, previous studies have suggested that 
HA in SCLC would be  safe16. Other studies showed that the HA technique reduced neurocognitive dysfunction. 
A prospective study suggested that hippocampal sparing may be beneficial for limiting the neuropsychological 
sequelae of brain radiation in SCLC  patients12. Although two patients (10% of their cohort) developed metastasis 
in an under-dosed brain region, the tumors were effectively treated with SRS. De Dios et al. also reported that 
the PCI group showed a significant decline in memory compared to the HA-PCI  group17. Moreover, a recent 
randomized phase III trial suggested that there was no significant difference in the incidence of brain metastases 
between standard PCI and HA-PCI according to their  abstract18. Although HA-PCI might be associated with an 
increased risk of brain metastasis in our analysis, it did not interfere with disease control or survival; therefore, 
to preserve the patients’ quality of life, HA-PCI should be considered. Moreover, most recurrences in the HA-
PCI group developed as a limited number of metastases and were treated with SRS and were well-tolerated. In 
the future, a prospective study should be conducted to assess whether HA-PCI for SCLC increases intracranial 
failure and neurologic death.
Several Japanese studies recommend close observation rather than PCI for SCLC patients. Ozawa et al. 
revealed that limited-stage SCLC patients who received PCI showed neither improved OS nor fewer brain 
 metastases19. They suggested that PCI was less beneficial if management with MRI and SRS was available. Further-
more, managing patients without PCI could improve  outcomes20. In a recent randomized phase 3 trial in Japan, 
compared with observation, PCI did not result in longer OS in SCLC patients with extensive stage  disease5. How-
ever, this approach could instill in patients and physicians’ anxiety and fear of recurrence with limited treatment 
options. According to the National Comprehensive Cancer Network guidelines, PCI is the standard treatment for 
Figure 3.  Comparison of disease-free survival (A) and overall survival (B) between the conventional 
prophylactic cranial irradiation (C-PCI) and hippocampus-avoidance (HA)-PCI groups.
Table 3.  Results of the Cox regression analyses for disease-free survival and overall survival. ECOG PS 
Eastern Cooperative Oncology Group Performance Status, AJCC American Joint Committee on Cancer, CTx 
chemotherapy, TRT Thoracic radiotherapy, EQD2 Equivalent dose in 2 Gy fractions, α/β = 10, Fx fraction, 
CR complete response, PR partial response, SD stable disease, HA-PCI hippocampal-avoidance prophylactic 
cranial irradiation, UVA univariate analysis, MVA multivariate analysis, HR hazard ratio.
Variables
Disease-free survival Overall survival
UVA MVA UVA MVA
HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p
Age (years) ≥ 65 (vs. < 65) 0.81 0.52–1.25 0.338 0.6 0.35–1.04 0.067 1.11 0.65–1.85 0.733 0.63 0.31 1.28
Sex F (vs. M) 0.91 0.46–1.82 0.792 0.56 0.23–1.36 0.197 0.49 0.15–1.58 0.232 0.98 0.12–1.74 0.968
ECOG PS 2 (vs. 0,1) 0.87 0.52–2.91 0.574 1.48 0.52–1.98 0.548 1.21 0.82–2.12 0.312 1.12 0.31–1.87 0.435
T stage T3, 4 (vs. T1, 2) 1.01 0.65–1.56 0.974 0.87 0.51–1.5 0.625 0.76 0.45–1.29 0.307 0.56 0.28–1.13 0.105
N stage N3 (vs. N0-2) 1.3 0.78–2.18 0.311 0.92 0.45–1.88 0.819 1.9 1.02–3.54 0.044 1.13 0.42–3.06 0.812
CTx cycles 6 (vs. 4) 1.13 0.71–1.79 0.62 1.15 0.66–2.01 0.616 0.89 0.51–1.58 0.7 1.15 0.58–2.3 0.689
TRT dose (EQD2, Gy) ≥ 60 (vs. < 60) 0.56 0.31–0.99 0.049 1.23 0.6–2.55 0.568 0.32 0.17–0.59 < 0.001 0.95 0.33–2.72 0.921
Treatment response PR/SD (vs. CR) 1.75 0.8–3.82 0.16 2.37 0.83–6.75 0.107 1.7 0.67–4.27 0.263 4.04 0.95–17.16 0.058
HA-PCI Yes (vs. No) 1.23 0.77–1.98 0.388 1.13 0.54–2.39 0.741 0.84 0.43–1.64 0.614 0.8 0.26–2.46 0.696
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both extensive and limited-stage SCLC, and methods of reducing neurocognitive dysfunction within the scope 
of PCI need to be determined. According to previous dosimetric studies, neurocognitive dysfunction occurs 
because the mean dose to the hippocampus exceeds approximately 19–20  Gy21. Besides HA-PCI, lowering the 
WBRT dose could be an alternative method. In cases of poor performance status, old age, or extensive stage, 
low-dose PCI may be useful.
As IMRT was covered by the national insurance program, had better dose coverage of the target volume, 
and spared OARs, both thoracic and cranial treatments were performed with IMRT. Despite more intensive 
treatment (i.e., higher thoracic RT doses and frequent use of 6 cycles of chemotherapy), patients in the HA-PCI 
group showed a lower CR rate than those in the C-PCI group. Although there was no difference in American 
Joint Committee on Cancer stage between the two groups, the aggressiveness of the tumors might have been 
different. It might be helpful to evaluate the actual tumor volume or Ki-67 index, which can determine tumor 
aggressiveness, and other known prognostic markers including serum lactate dehydrogenase and C-reactive 
protein. However, due to the retrospective nature of this study and long study period, such information was 
not fully evaluated. This is one of the limitations of this study. Nevertheless, the CR rate was not significant for 
patient survival, and DFS and OS did not differ between the two groups.
There is a lack of evidence on dose-escalation for SCLC, and 45 Gy in 30 fractions twice daily is the standard 
 regimen22. However, several studies suggested the safety and efficacy for dose-escalation for  SCLC23. In the era 
of IMRT, administering a higher dose may be recommended, especially for controlling bulky and less-responsive 
primary tumors. We should thus wait for the results of CALGB 30610-RTOG 0538, a randomized phase III dose-
escalation trial for limited-stage SCLC.
This study had several limitations. First, because of the study’s retrospective nature, neurocognitive functions 
before and after PCI were not evaluated; therefore, we could not demonstrate the benefit of HA-PCI. In addition, 
it was not possible to clearly identify the schedule of brain metastasis evaluation at each period. Second, the 
number of events was insufficient to identify a statistically significant variable. Third, since we included patients 
for a relatively long period (12 years), differences in patient and treatment selection could exist between the two 
groups. Patients in the HA-PCI group were recently diagnosed and treated. Although recent patients received a 
higher thoracic RT dose with IMRT, brain metastasis might have been detected earlier owing to a careful follow-
up course in these patients.
In conclusion, although HA-PCI may be associated with an increased risk of intracranial failure, all peri-
hippocampal recurrences were marginal recurrences, and relatively sufficient doses were administered. Further-
more, HA-PCI did not affect disease control and OS. The results of the prospective randomized phase II/III trial, 
NRG-CC003, will help to draw definite conclusions.
Materials and methods
Study population. All methods were carried out in accordance with relevant guidelines and regulations. 
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as revised in 1983, 
and was approved by the Institutional Review Board of Yonsei University Health System (IRB protocol num-
ber: 4-2019-0855). The patient records/data were anonymized and de-identified prior to analysis, and informed 
consent was not obtained from the participants. As this was a retrospective study, it was impossible to proceed 
with the study without an exemption of consent; this was approved by the IRB on the condition of anonymiza-
tion of patient’s personal data. Between 2006 and 2018, the medical records of patients diagnosed with limited-
stage SCLC without distant metastasis were retrospectively reviewed. Patients who received radiotherapy with or 
without chemotherapy or surgery and showed a favorable response to initial treatment were candidates for PCI. 
Patients were excluded if they had previously received overlapping irradiation, brain metastases, other distant 
metastasis, or a history of another malignancy within the past 5 years.
Treatment planning. As IMRT has been covered by the national insurance program since 2015, most of 
the patients received thoracic RT with IMRT; PCI was also conducted with IMRT after 2015. Moreover, as the 
patients’ quality of life became more important, the preservation of neurocognitive function has become essen-
tial in the treatment process. Treatment planning was based on planning computed tomography (CT) without 
an intravenous contrast agent but with 1–3-mm-thick slice intervals.
For HA-PCI planning, 3D-T1W MRI sequences were fused to their planning CT scans for hippocampal 
contouring. The anatomic boundaries of the hippocampus were identified according to a previous  protocol10,24, 
and based on current recommendations of RTOG 0933, 5-mm volumetric expansion was considered from 
the hippocampus to create an HA  zone11. The HA-PCI plan was generated, in which the mean dose to the hip-
pocampus was < 10 Gy and the maximum dose was < 16–17 Gy. Daily mega-voltage CT guidance was also used.
Follow‑up. In general, PCI was performed within 1 month after the end of the last treatment. Before the start 
of PCI, thoracic disease control was evaluated mainly with chest CT 1–4 weeks after the initial treatment. The 
response to the initial treatment was evaluated by radiologists using the Response Evaluation Criteria in Solid 
Tumors criteria and categorized as CR, PR, stable disease, or progressive disease.
After PCI, it was suggested that patients visit the hospital every 3 months for 5 years, and brain MRI was 
performed at least once a year. If there was evidence of brain metastasis, namely a neurologic symptom, pri-
mary tumor progression, or metastasis to another site, additional brain evaluation was performed. For patients 
who developed brain metastases, T1 post-gadolinium MRI at the time of intracranial failure was manually co-
registered into the MIM vista system (MIM Software, Inc, Cleveland, Ohio) for dosimetric data, including the 
location, irradiation dose, and the volume of each lesion.
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Statistical analysis. Survival and time to recurrence were estimated using the Kaplan–Meier method, and 
the differences between groups were compared using the log-rank test. Differences in clinical factors between the 
HA-PCI and C-PCI groups were compared using Fisher’s exact test. Continuous data were compared between 
the groups using the Mann–Whitney U test. DFS was defined as the time from the date of first treatment to the 
date of detection of any recurrence, including locoregional, distant, and intracranial failures. OS was defined as 
the interval from the date of first treatment to death. Univariate and multivariate analyses for intracranial fail-
ure, DFS, and OS were conducted using the Cox proportional hazards model. Furthermore, a multivariate Cox 
hazard regression analysis was performed using all clinical variables used in univariate analysis; the results were 
reported as HRs with their corresponding 95% CIs. P values < 0.05 were considered statistically significant. All 
analyses were performed using IBM SPSS, version 24.0 (SPSS, Chicago, IL, USA). The datasets generated during 
and/or analysed during the current study are available from the corresponding author on reasonable request.
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